Lonza Group AG (LZAGY) Stock Price & Analysis
Lonza Group AG (LZAGY) — price $79.11 (+0.23%), as of the Nov 19, 2026 trading session; market cap $56.3B.
Educational signal · not a buy or sell recommendation · How to read this
Lonza Group AG · LZAGY · Healthcare · Biotechnology
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $79.11 | |
| Change on the day | +0.23% | |
| 52-week range | $58.53–$82.63 | |
| Market capitalisation | $56.3B | — |
| Price / earnings (trailing) | 41.62 | |
| Shares traded on the day | 38.1K | |
| Beta (volatility vs the S&P 500) | 0.84 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Lonza Group AG (LZAGY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Lonza Group AG (LZAGY), and what does it report?
Short answer · as of
Lonza principally sells development, scale-up and manufacturing capability rather than relying on an internal drug pipeline.
Research dated 2026-09-12.
Its customers buy support across biologics, small molecules, cell and gene therapies, personalized medicine, capsules, dosage forms and health ingredients.
Revenue therefore reflects customer programs moving through development and manufacturing, along with commercial demand flowing through installed capacity. The quoted security trades over the counter, while the operating statements describe the broader Lonza Group and its mix of service and product businesses.
What do the latest results show for Lonza Group AG (LZAGY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 3.45B. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 3.45B | CHF 604M | CHF 0.86 (diluted) |
| Q4 FY2025 | CHF 2.96B | CHF 523M | CHF 0.75 (diluted) |
| Q2 FY2025 | CHF 3.58B | CHF 426M | CHF 0.61 (diluted) |
| Q4 FY2024 | CHF 3.52B | CHF 307M | CHF 0.43 (diluted) |
What are the financial strengths and risks for Lonza Group AG (LZAGY)?
Short answer · as of
The distress and quality screens read Altman Z 4.30 · Piotroski F 8. Trailing ratios: ROE 13.9% · ROA 6.1% · current ratio 1.66 · earnings yield 2.4% · free-cash-flow yield 0.3%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Rich valuation — a P/E of 41.62 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LZAGY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LZAGY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Lonza Group AG (LZAGY)?
What Investors Ask About Lonza Group AG (LZAGY) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
What does Lonza's Biologics segment sell?
Biologics provides contract development and manufacturing across clinical and commercial stages. Demand follows customer therapies as they advance, scale and require ongoing production.
Why does Lonza's extended site shutdown matter for sales?
The shutdown allows capital work to progress but removes manufacturing availability during part of the period. Management expects that interruption to offset earlier performance and leave the affected operation broadly flat.
What is the LZAGY stock price today?
The last price recorded for Lonza Group AG (LZAGY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 13 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com